Supernus Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€570.68M - Cost of goods sold
€100.97M - Gross profit
€453.54M - SG&A expenses
€286.28M - R&D expenses
€90.63M - EBITDA
€142.46M - D&A
€69.20M - EBIT
€54.17M - Interest expenses
€0.00 - EBT
€70.50M - Tax expenses
€15.16M - Net income
€55.34M
Cash flow statement
- Net deferred tax
-€15.18M - Non-cash items
€20.47M - Changes in working capital
€10.63M - Operating cash flow
€160.50M - Capex
€1.03M - Other investing cash flow
€7.72K - Net investing cash flow
-€71.16M - Total cash dividends paid
€0.00 - Issuance of common stock
€13.43M - Debt repayment
€0.00 - Other financing cash flow
-€23.30M - Net financing cash flow
-€9.87M - Foreign exchange effects
€0.00 - Net change in cash
€79.47M - Cash at end of period
€124.16M - Free cash flow
€161.52M
Balance sheet
- Cash and cash equivalents
€124.16M - Cash and short-term investments
€448.39M - Total receivables
€120.83M - Inventory
€37.77M - Other current assets
€26.95M - Total current assets
€633.95M - Property, plant & equipment
€28.27M - Goodwill
€100.40M - Intangible assets
€412.96M - Long-term investments
€0.00 - Other non-current assets
€5.22M - Total non-current assets
€552.16M - Total assets
€1.19B - Accounts payable
€7.05M - Short-term debt
€6.34M - Other current liabilities
€232.31M - Total current liabilities
€245.70M - Long-term debt
€41.84M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€6.66M - Total non-current liabilities
€27.58M - Total liabilities
€273.28M - Common stock
€48.05K - Retained earnings
€486.57M - Other equity
-€171.60K - Total equity
€912.83M - Total liabilities and shareholders' equity
€1.19B
Company information
- Market capitalization
€1.49B - Employees
674 - Enterprise Value
€1.77B
Company ratios
- Gross margin
-
79.5% Much worse than peer group: 524.8% - EBITDA margin
-
25.0% Much worse than peer group: 1,051,300.1% - EBIT margin
-
9.5% Much worse than peer group: 990,054.8% - EBT margin
-
12.4% Much worse than peer group: 1,051,618.2% - Net margin
-
9.7% Much worse than peer group: 953,386.2% - ROE
-
6.1% Better than peer group: -11.8% - ROA
-
4.7% Better than peer group: -9.7% - Asset turnover
-
48.1% Worse than peer group: 53.8% - FCF margin
-
27.9% Much worse than peer group: 739,526.0% - FCF yield
10.7% - Efficiency ratio
75.0% - Net sales per employee
-
€846.70K - Net income per employee
-
€82.10K